Daniel Goldman is an Ophthalmology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3333 Bayshore Blvd
Suite 280
Pasadena, TX 775041952
Telephone
713-943-8671Provider last certified this registry record 25 Oct 2022.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202512 payments
- Astellas Pharma US IncProgram year20253 payments
- Bausch & Lomb Americas Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
62.5%Prostaglandin Analog29.7%Latanoprost82%Lumigan10%Travoprost8%Part D<11 patientsCarbonic Anhydrase Inhibitor16.4%Dorzolamide-Timolol84%Simbrinza16%Part D≥57 patients+ 7 more classes in this area
Cancer & immunology
29.4%Vascular Endothelial Growth Factor Inhibitor29.4%Aflibercept85%Bevacizumab16%Part B, office-administered≥37 patientsAnti-infectives
4.3%Macrolide3.2%Erythromycin100%Part D≥35 patientsFluoroquinolone Antibacterial1.1%Moxifloxacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”